Waking in the night during menopause: estrogen, melatonin and sleep apnea
Night waking, hot flashes and daytime sleepiness can overlap. This archive article explores clues to chronic insomnia and obstructive sleep apnea, and what to bring to an appointment.

In this article
Cover of the original archive edition: Fisherman's Bastion, Budapest | Photograph by Perituss | CC0 (cropped, resized and overlaid with cover text).
Scope: This article reviews research and academic literature. It does not provide a diagnosis or treatment recommendation, or endorse any product or brand. Management of insomnia and sleep-related breathing disorders should be decided by sleep and gynaecology or menopause specialists in light of the individual circumstances. MHT (menopausal hormone therapy) is often called HRT in the United States.
1. Executive summary
Sleeping through the night can seem to slip away in perimenopause. More women in midlife find that their problem is not falling asleep. They wake repeatedly during the night, wake too early in the morning and struggle with fatigue through the day. This disruption rarely has a single cause. Estrogen withdrawal alters temperature regulation and sleep architecture. Melatonin declines with age and can contribute to later sleep onset. Obstructive sleep apnea (OSA), long overlooked in women, often looks like insomnia. Anxiety, hot flashes and awakenings can feed into one another. This review follows the four strands, how each works and how they interact, to explain why assessment should come before choosing a treatment. Menopausal insomnia deserves attention. Working out whether hormones, breathing or psychological factors predominate helps match treatment to the cause.
Key figures at a glance
- SWAN cohort: moderate to severe sleep-disordered breathing (AHI >15/hour) was reported in about 20% of midlife women, compared with about 4% before menopause. AHI increased by about 4% for each additional year in the menopause transition.
- Ohayon and colleagues: about 26% of perimenopausal women met DSM-IV criteria for insomnia. Difficulty staying asleep was the most common pattern.
- A 2025 Obstetrics & Gynecology review: OSA prevalence was about 47% after menopause versus about 21% before menopause, and the association was independent of BMI.
- Persistent insomnia was associated with about 70% higher cardiovascular event risk. Insomnia with short sleep was associated with about 75% higher risk.
- Yi's 2021 meta-analysis (n=812): melatonin significantly improved menopausal somatic symptoms (SMD −0.376, P=0.001), with no significant benefit for sleep quality (P=0.141).
Budapest:
Heroes' Square in Budapest
| Photograph by Slyronit |
CC BY-SA 4.0
(Cropped and resized)
2. Estrogen withdrawal and difficulty staying asleep
Estrogen has functions beyond reproduction and affects the brain's sleep and wake systems in several ways. It helps regulate body temperature, which helps explain why hot flashes and night sweats are tied to interrupted sleep. It influences the reuptake of serotonin and norepinephrine and acts on networks that help maintain slow-wave and REM sleep. As estrogen fluctuates and declines in perimenopause, sleep architecture is disrupted. Deep sleep decreases, light sleep increases and awakenings become more frequent, leaving people feeling as though they barely slept. A typical complaint is waking at two or three in the morning and struggling to fall asleep again, or waking two to three hours earlier than intended, rather than difficulty initially falling asleep. In a PLOS ONE study, Triebner and colleagues also found that a doubling of estrone was associated with about 19% lower odds of snoring, and a doubling of pregnenolone or progesterone with about 9% lower odds. The findings suggest that sex hormones may also influence upper airway tone.
2.1 The cycle of hot flashes and awakening
For many midlife women, sleep disruption arises when vasomotor symptoms (VMS) interrupt sleep. A hot flash and sweating can pull someone out of deep sleep. The heart rate and body temperature may still be elevated on waking, and it takes time to fall asleep again. Studies using actigraphy and polysomnography (PSG) have found a significant positive correlation between the frequency of VMS and the frequency of nocturnal awakenings. Prolonged sleep deprivation can also raise sympathetic nervous system activity and heighten the perception of hot flashes. The more often you wake, the more sensitive you can become, and that sensitivity can make waking more likely. This helps explain why sleeping pills alone may have a limited effect when VMS remain a trigger.
3. Melatonin and the limits of a “natural” sleep aid
A common misconception is that melatonin is a sleeping pill without side effects. Two points matter here. First, endogenous melatonin, produced by the pineal gland, does decline with age, and this is associated with taking longer to fall asleep. Second, the evidence that supplemental melatonin improves sleep quality during menopause is unconvincing. A 2021 meta-analysis by Yi and colleagues (eight cohorts, n=812) found significant improvement in menopausal somatic symptoms (SMD −0.376, P=0.001), with no significant improvement in sleep quality (SMD −0.659, P=0.141) or overall menopausal symptoms (P=0.093). Amstrup's 2015 study (N=81 postmenopausal women with low bone mass, 1 or 3 mg for 12 months) suggested it was safe without next-day grogginess, with a trend towards improvement only in the poor-sleep subgroup (p=0.08). A 2024 randomised controlled trial (N=41 healthy postmenopausal women, 10 mg for three months) found no significant improvement in sleep, blood pressure or arterial stiffness. Professional resources such as the Australasian Menopause Society's February 2025 sleep page frame melatonin as an option for short-term changes in sleep timing, such as jet lag or shift work, and do not recommend it routinely for chronic insomnia.
3.1 Retraction alert for a meta-analysis that reported a benefit
When reviewing the evidence on melatonin in menopause, check the status of Zhang and colleagues' 2023 meta-analysis in the Journal of Healthcare Engineering. The journal retracted the paper. If you read a claim that melatonin significantly improves perimenopausal sleep, check where it came from before relying on the conclusion. Clinical and health writers should check whether studies they cite remain in good standing. A retracted meta-analysis can be more misleading than a negative result because it presents an effect as reliable without a sound basis. When a patient tells a clinician that melatonin seems to help, the clinician can explore whether sleep improved and whether the change could reflect a placebo effect or a change in schedule before deciding whether to continue.
Budapest:
The Hungarian Parliament Building beside the Danube
| Photograph by Godot13 |
CC BY-SA 4.0
(Cropped and resized)
4. When sleep apnea in women looks like insomnia
Obstructive sleep apnea (OSA) has long been associated with middle-aged men who snore loudly, feel sleepy during the day and have breathing pauses noticed by a partner. In women, especially from perimenopause onwards, the presentation is often less typical. A woman may come to the clinic with insomnia, fatigue, morning headaches or low mood, without loud snoring, and the condition may be missed. SWAN reported that about 20% of midlife women had moderate to severe sleep-disordered breathing (AHI >15/hour), compared with about 4% before menopause, with AHI increasing by around 4% for each additional year in the transition. Freedman and Roehrs found that as many as 53% of midlife women reporting sleep difficulties also had sleep-disordered breathing or periodic limb movements. A 2025 review in Obstetrics & Gynecology summarised an OSA prevalence of about 47% after menopause and 21% before menopause, independent of BMI. The original review links this to estrogen withdrawal and to possible effects on upper airway muscle tone, respiratory drive and fat distribution.
4.1 When to consider OSA before prescribing a sleep aid
Clues that warrant screening, such as with STOP-Bang, the Berlin questionnaire or referral for polysomnography, include snoring, even if quiet, waking short of breath or choking, waking with a dry mouth or headache, irresistible daytime sleepiness, resistant hypertension, or insomnia that responds poorly to antidepressants or sleeping pills. An important pitfall is prescribing a sedative or hypnotic to a woman reporting insomnia when the underlying problem is OSA. Some sedatives can further relax the upper airway and aggravate apnea. Sleep medicine emphasises using a sleep complaint during perimenopause as a chance to consider OSA before moving directly to sleeping pills. Normal weight or an absence of snoring does not rule out OSA in women.
4.2 Why OSA becomes more common after menopause
OSA in women increases after menopause independently of BMI, and the mechanism is multifactorial. After estrogen withdrawal, fat redistributes from subcutaneous stores, particularly around the hips and thighs, to the abdomen and around internal organs, and potentially to the neck and upper airway. The airway can become more prone to collapse when lying on the back and during sleep. Progesterone has a mild respiratory stimulant effect that increases the ventilatory response to carbon dioxide, so declining progesterone can further weaken ventilatory drive during sleep. Upper airway dilator muscle tone and the central chemosensitivity to low oxygen and high carbon dioxide also decrease as hormone levels fall. The article uses these mechanisms to explain how a postmenopausal woman with a normal BMI can still have moderate to severe OSA. In perimenopausal women with insomnia, asking about snoring, waking up gasping and daytime sleepiness can bring screening forward even at a normal BMI.
Budapest:
Széchenyi Chain Bridge and the Danube
| Photograph by Frank Schulenburg |
CC BY-SA 3.0
(Cropped and resized)
5. Orexin antagonists and sleep maintenance
Conventional sedative-hypnotics, including benzodiazepines and Z-drugs, can help with falling asleep, but they often alter sleep architecture, carry risks of next-day grogginess and falls, and are not suited to long-term use in this account. Dual orexin receptor antagonists (DORAs) work differently. They inhibit the wake-promoting orexin signal and help sustain sleep. In a 2023 Menopause post hoc analysis of SUNRISE-2, Terauchi and colleagues studied midlife women aged 40–58 (N=280, lemborexant 10 mg) and reported a shorter time to fall asleep (P=0.031), higher sleep efficiency, longer total sleep time and less wakefulness after sleep onset (WASO). In the archive's account of a four-week suvorexant study by Rahman and colleagues (N=57, mean age 54.3), the Insomnia Severity Index (ISI) fell by −8.1 versus −5.6 (P=0.04), and nighttime VMS frequency also declined significantly (P<0.01). That suggests a possible effect on the combination of awakenings and hot flashes. DORAs are approved for insomnia in some jurisdictions. The archive flags pregnancy, severe liver impairment and narcolepsy-related cataplexy as contraindications and calls for a physician's assessment before use.
Budapest:
St Stephen's Basilica in Budapest
| Photograph by Carlos Delgado |
CC BY-SA 3.0
(Cropped and resized)
6. MHT and sleep when symptoms are driving awakenings
If VMS are the main trigger for insomnia, treating VMS can often improve sleep. The archive cites China's 2024 expert consensus on diagnosing and treating insomnia in specific populations and the 2025 Chinese insomnia guideline commentary. It describes perimenopausal MHT (called HRT in the US) as improving insomnia, shortening sleep onset and reducing awakenings, and reports possible benefit from supplemental melatonin or melatonin receptor agonists (MRAs). Micronised progesterone is metabolised to allopregnanolone, which can promote sleep and reduce anxiety, and may be helpful where staying asleep is difficult. Gabapentin can address hot flashes and also has a sedating effect. It can be considered for people for whom MHT is unsuitable or who prefer to defer it. MHT has indications, contraindications and considerations around timing. It should be initiated with a menopause specialist's assessment. Ask the clinician to help make the decision while retaining the right to be informed.
Nighttime awakenings: clues and tests to discuss
| Main clue | What to clarify first | What to discuss at the visit |
|---|---|---|
| Waking after night sweats or hot flashes | Whether vasomotor symptoms are driving the awakenings | Record hot flashes and sleep timing. Assess whether symptom treatment is indicated. |
| Snoring, morning headache or daytime fatigue | OSA in women can look like insomnia | Screen for OSA and consider sleep monitoring when indicated. |
| Insomnia lasting ≥3 months | Whether the criteria for chronic insomnia are met | Prioritise a discussion of cognitive behavioural therapy for insomnia (CBT-I). |
| Disrupted sleep timing | A circadian problem differs from chronic difficulty staying asleep | Melatonin does not replace assessment for chronic insomnia. |
This table from the original maps symptoms to questions for assessment. Symptoms can coexist. A single symptom should not be used to self-diagnose or self-medicate.
Rahman and colleagues' randomised trial, n=56 (27 intervention, 29 control). At four weeks, ISI scores fell by 8.1 and 5.6 points, respectively, p=0.04. Some passages in the original give 57 as the sample size. The added figure follows the numbers presented as trial data. Changes in ISI points must not be read as counts of awakenings.
Chart source
6.1 Matching treatment to the dominant factor
Management of menopausal insomnia starts with identifying the main factor, then matching care to it, rather than prescribing the same sleeping pills to everyone. When VMS predominate, the archive prioritises MHT or nonhormonal symptom treatment (gabapentin, SSRIs or SNRIs such as low-dose paroxetine, clonidine, or the NK3 antagonist fezolinetant). When OSA predominates, it prioritises continuous positive airway pressure (CPAP) or an oral appliance over sedatives. Where psychological or behavioural factors predominate, it places CBT-I first. For isolated sleep-onset difficulty and a short-term need, it mentions low-dose melatonin or a DORA as options for consideration. The hormonal, respiratory and behavioural strands can be addressed together. In complex cases involving several factors, a joint assessment by sleep and menopause specialists can be particularly valuable.
Budapest:
A Budapest street with a tram
| Photograph by Pallor |
CC BY 4.0
(Cropped and resized)
7. CBT-I as first-line care for chronic insomnia
Regardless of how complex the cause is, when insomnia has become chronic (≥3 months, ≥3 nights per week), cognitive behavioural therapy for insomnia (CBT-I) is the first choice in guidelines. The Australasian Menopause Society's February 2025 sleep page and the Chinese insomnia guideline take this position. CBT-I includes sleep restriction, stimulus control, sleep hygiene education, cognitive restructuring and relaxation. It is drug-free, non-addictive and can have lasting effects. The 2016 MsFLASH study found CBT-I effective against perimenopausal insomnia, with effects maintained at six months. For women in the menopause transition it can help interrupt the cycle of worrying that they will not sleep, then sleeping worse as a result, a psychological factor that hormone treatment does not address. Digital CBT-I through an app or online course can offer additional access where resources are limited. Severe cases or cases involving a psychiatric condition still warrant in-person professional care.
Five clinical points at a glance
- Identify the main contributor first. Address hot flashes when VMS predominate, CPAP when OSA predominates and CBT-I when psychological factors predominate. Avoid jumping straight to sleeping pills.
- Melatonin evidence. Significant improvement in somatic symptoms but no significant benefit for sleep quality. Short-term adjustment of sleep timing only in the archive's summary. Zhang's 2023 paper was retracted.
- OSA in women. It may appear as insomnia, fatigue or mood symptoms, independently of BMI. SWAN reported 20% moderate to severe sleep-disordered breathing. Screening should consider more than BMI.
- MHT and newer medicines. Micronised progesterone and allopregnanolone can promote sleep. DORAs (lemborexant or suvorexant) may help to sustain sleep and may reduce VMS.
- CBT-I first. First choice for chronic insomnia (>3 months). MsFLASH found benefits held at six months. The archive reserves medicines for very short-term or targeted symptom treatment.
Budapest:
Buda Castle and Castle Hill
| Photograph by Jakub Hałun |
CC BY-SA 4.0
(Cropped and resized)
8. Guidance for readers in China and preparing for an appointment
If you keep waking in the middle of the night, three things are worth remembering. First, the problem deserves a proper assessment. Hormones, breathing and mood can all play a part. Second, before stocking up on melatonin or sleeping pills, clarify whether hot flashes, snoring or anxiety are driving the problem. Third, long-standing sleep problems can raise cardiovascular and mood risks and deserve attention. Treat sleep as a health measure you can record. For families, the exhaustion of waking alone at night and the sleepiness and irritability the next day are part of a physical experience that can be addressed. “How did you sleep last night?” can be more helpful than “Just go to bed earlier.”
Checklist to bring to a sleep or menopause clinic
- A two-week sleep diary: bedtime, time to fall asleep, number of awakenings, time you get up and degree of daytime sleepiness.
- Frequency of hot flashes or night sweats and whether they interrupt sleep, plus menstrual status (perimenopause or postmenopause).
- Snoring, waking gasping, morning headaches and daytime sleepiness that is hard to control (possible OSA clues).
- Medications and supplements already taken, including melatonin, sleep aids and antidepressants, and how you responded.
- Anxiety and depression self-screening, blood pressure, weight and BMI, and any thyroid or ferritin results to help assess other causes of insomnia.
9. Eight research notes for clinicians
1. SWAN (Study of Women's Health Across the Nation). About 20% of midlife women had moderate to severe sleep-disordered breathing (SDB, AHI >15/hour) versus about 4% before menopause. AHI increased by about 4% for each additional year in the transition. Sleep-disordered breathing increased across the transition.
2. Ohayon et al., insomnia epidemiology survey. Around 26% of perimenopausal women met DSM-IV criteria for insomnia. Trouble staying asleep was the most common pattern.
3. Obstetrics & Gynecology, 2025 review. OSA was reported in about 47% after menopause versus 21% before menopause, independently of BMI. Persistent insomnia was associated with about 70% higher CVD risk and insomnia with short sleep with about 75% higher risk.
4. Triebner et al., PLOS ONE. A doubling of estrone was associated with 19% lower odds of snoring, and a doubling of pregnenolone or progesterone with 9% lower odds. The archive discusses an inverse association of sex hormone concentrations with snoring and a possible link to upper airway tone.
5. Yi et al., 2021 meta-analysis (n=812). Melatonin significantly improved somatic symptoms (SMD −0.376, P=0.001), with no significant benefit for sleep quality (P=0.141) or overall symptoms (P=0.093).
6. Terauchi et al., Menopause 2023 (SUNRISE-2 post hoc analysis). Midlife women aged 40–58, N=280. Lemborexant 10 mg shortened sleep onset (P=0.031), improved sleep efficiency, lengthened total sleep time and reduced time awake after falling asleep.
7. Rahman et al., suvorexant study. The archive gives N=57 and mean age 54.3. At four weeks the ISI change was −8.1 versus −5.6 (P=0.04), and nighttime VMS frequency fell (P<0.01).
8. MsFLASH 2016 and the 2025 Chinese insomnia guideline. CBT-I was effective for perimenopausal insomnia, with benefits maintained at six months. The archive describes perimenopausal MHT as improving insomnia, shortening sleep onset and reducing awakenings, and reports possible benefit from melatonin or MRAs.
10. Conclusion
Menopausal insomnia can be hard to manage because several factors can contribute at once. Estrogen withdrawal can disrupt sleep architecture. Melatonin is often overestimated and misused. OSA may be missed when it looks like insomnia. Anxiety and awakenings can reinforce each other. The way forward begins by examining each strand and letting go of the idea that people should endure the symptoms or that one pill will solve them all. Address hot flashes when VMS are driving symptoms, consider CPAP when breathing is the main issue and use CBT-I for psychological and behavioural contributors. MHT or a DORA may be considered when appropriate to help with sleep maintenance. Readers can take a full sleep diary to a relevant specialist, ask to be informed and make decisions together with their clinician. Women waking in the middle of the night deserve to be heard and offered an assessment of the possible causes. Saying “everyone goes through it” can allow a treatable sleep problem to become chronic.
Scope: This article is for public education and reviews academic literature. It does not provide a diagnosis or treatment recommendation, or endorse a particular product, brand or therapy. Use of MHT, DORAs, CBT-I or CPAP should be decided by sleep and gynaecology or menopause specialists with the individual's circumstances in mind. If red flags arise, seek medical attention promptly.
Red flags that call for prompt medical attention
- A partner notices breathing pauses or gasping during sleep, or you frequently wake short of breath or choking (possible OSA).
- Irresistible daytime sleepiness or suddenly falling asleep while driving or at work (possible severe sleep-disordered breathing).
- Insomnia lasting >3 months despite usual sleeping medication, or accompanied by pronounced low mood or anxiety.
- Morning headaches, resistant hypertension or nighttime angina (possible overlap between sleep-disordered breathing and cardiovascular risk).
- Suicidal thoughts or severe depression (needs prompt specialist mental health support).
This article is for evidence-based education. Bring relevant information and discuss decisions with your treating clinician.
Read the source material
- AASM guideline on behavioural and psychological treatments for chronic insomnia
- AASM guideline on diagnostic testing for adult obstructive sleep apnea
- Rahman et al., randomised trial in vasomotor symptom-associated insomnia
- MsFLASH trial of CBT-I in peri- and postmenopausal women
The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.
A good question starts a conversation.
Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.


